Research programme: immunotherapeutic vaccines - Aastrom/Stanford University

Drug Profile

Research programme: immunotherapeutic vaccines - Aastrom/Stanford University

Alternative Names: CIK therapy - Aastrom/Stanford University; Cytokine induced killer cell therapy - Aastrom/Stanford University; Dendricell

Latest Information Update: 18 May 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aastrom Biosciences; Stanford University
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Epstein-Barr virus infections; Hodgkin's disease; Multiple myeloma

Most Recent Events

  • 18 May 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 18 May 2006 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
  • 18 May 2006 Discontinued - Preclinical for Epstein-Barr virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top